TrialFrontiers in immunology2022

Predicting Pathological Complete Response in Neoadjuvant Dual Blockade With Trastuzumab and Pertuzumab in HER2 Gene Amplified Breast Cancer.

Yi Xiao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.